Herantis Pharma Plc, Company release, 21 February 2023 at 1:00 p.m. EET
Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, announced today that it will release 2H & FY 2022 Report on Thursday, March 2, 2023, at 08:00 EET/ 07:00 CET.
Members of the Herantis’ Management team will hold a live webinar to provide more details on the 2H & FY 2022 Report with a live Q&A session (in English) at 10:00 EET / 9:00 CET on the same day.
Please join the webinar a few minutes in advance.
Register for Herantis Pharma’s 2H & FY 2022 Report webinar here: Click Here to Register
Registation is required for this event. To register for this event you need a Zoom account. After registering, you will receive a confirmation email containing information about joining the webinar.
Questions can be submitted throughout the webcast event.
Following the webcast of the live call, a recording will be available on Herantis Pharma’s website:https://herantis.com/news-events/video-presentations/
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
For more information, please visit www.herantis.com